Enhanced Degradation of Platelet-Activating Factor in Serum from Diabetic Patients

Hofmann, B; Rühling, K.; Spangenberg, P; Ostermann, G

doi:10.1159/000215913

Cited by 13 publications

(12 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of our study showed that the serum PAF-AH activity in heterozygous FH patients is significantly higher than that of normolipidaemic control subjects. Changes in the activity of serum PAF-AH have been associated with several human diseases [27][28][29], and some studies have demonstrated the existence of a good correlation between PAF-AH activity and disease activity [30]. However, as has been reported, there is a marked excess of enzyme in serum under basal conditions, while a reduction in the enzyme activity by as much as 50% would not increase the half-life of PAF in blood [31].…”

Section: Discussionmentioning

confidence: 96%

Increased activity of platelet‐activating factor acetylhydrolase in low‐density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia

Karabina

Elisaf²,

Bairaktari

et al. 1997

Eur J Clin Investigation

View full text Add to dashboard Cite

Patients with heterozygous familial hypercholesterolaemia (FH) have elevated plasma concentrations of low-density lipoprotein (LDL) and develop premature atherosclerosis. There is increasing evidence that oxidative modification of LDL is important for the pathogenesis of atherosclerosis, and the LDL-associated platelet-activating factor acetylhydrolase (PAF-AH) seems to play a key role in LDL oxidation by hydrolysing the oxidized phospholipids of phosphatidylcholine (PC) and producing lysophosphatidylcholine (lyso-PC). We measured the total serum and high-density lipoprotein (HDL) levels of PAF-AH activity and studied the distribution of PAF-AH activity among three LDL subfractions isolated by gradient ultracentrifugation in 15 patients with heterozygous FH and 13 normolipidaemic control subjects. We also determined the lyso-PC production in each LDL subfraction during Cu2(+)-induced oxidation in vitro. The total serum PAF-AH activity in heterozygous FH patients was significantly higher than in control subjects, whereas the HDL-associated PAF-AH activity, expressed as a percentage of total serum PAF-AH activity, was significantly lower in the FH patients than in control subjects (13.9 +/- 6.6% vs. 30.6 +/- 4.4%, P < 0.001). Among the LDL subfractions, the PAF-AH activity in both normolipidaemic control subjects and FH patients, expressed as nmol mg-1 protein min-1, was significantly higher in the LDL3 subfraction (33.1 +/- 4.8 and 53.4 +/- 11.5 respectively) than in the LDL2 (18.6 +/- 5.3 and 26.8 +/- 10.4 respectively, P < 0.0001 for both comparisons) and LDL1 subfractions (5.1 +/- 1.5 and 7.8 +/- 2.6, respectively, P < 0.0001 for both comparisons). Additionally, the enzyme activity in each LDL subfraction of the heterozygous FH patients was significantly higher than in control subjects (P < 0.02 for LDL1, P < 0.03 for LDL2 and P < 0.0001 for LDL3). No difference was observed in the susceptibility to oxidation of each LDL subfraction among the heterozygous FH patients and the normolipidaemic control subjects. During oxidation, the PAF-AH activity decreased, whereas the lyso-PC levels significantly increased in all subfractions of both groups. The lyso-PC/sphingomyelin molar ratio in each LDL subfraction of the FH patients 3 h after the onset of the oxidation was significantly higher than in control subjects [0.38 +/- 0.05 and 0.27 +/- 0.04, respectively, for LDL1 (P < 0.006), 0.47 +/- 0.08 and 0.39 +/- 0.03, respectively, for LDL2 (P < 0.04), 0.55 +/- 0.11 and 0.42 +/- 0.06, respectively, for LDL3 (P < 0.02)]. Our results show that heterozygous FH patients exhibit higher PAF-AH activity than control subjects in all LDL subfractions, resulting in higher lyso-PC production during oxidation, which confers on these subfractions higher biological potency. This phenomenon, in combination with the diminished anti-atherogenic and antioxidant capability of HDL in these patients due to the relatively low HDL-cholesterol levels compared with LDL-cholesterol levels and, consequently, the relatively low HDL-associated PAF-AH...

show abstract

Section: Discussionmentioning

confidence: 96%

Increased activity of platelet‐activating factor acetylhydrolase in low‐density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia

Karabina

Elisaf²,

Bairaktari

et al. 1997

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…The plasma activity of this enzyme has been shown to increase during the "stress" reaction of the lizard (7). in patients with ischemic cerebrovascular disease (8), with insulin-dependent diabetes mellitus (9), in spontaneous hypertensive rats (lo), and in Caucasian males with hypertension (1). The plasma activity is decreased in asthmatic children (1 I ) and in the maternal plasma during the latter stages of pregnancy (12).…”

mentioning

confidence: 99%

Platelet-Activating Factor–Induced Ischemic Bowel Necrosis: The Effect of Platelet-Activating Factor Acetylhydrolase

1993

View full text Add to dashboard Cite

“…The pancreas may produce PAF under normal conditions, but a relation between PAF signalling and the secretion of pancreatic hormones and insulin is not yet defined. PAF acetylhydrolase activity was increased in plasma from patients with diabetes mellitus [41]. and in urine from patients with diabetic nephropathy [49].…”

Section: Diabetic Diseasesmentioning

confidence: 98%

Platelet‐activating factor: a mediator for clinicians

Imaizumi

Stafforini

Yamada

et al. 1995

Journal of Internal Medicine

148

View full text Add to dashboard Cite

Enhanced Degradation of Platelet-Activating Factor in Serum from Diabetic Patients

Cited by 13 publications

References 15 publications

Increased activity of platelet‐activating factor acetylhydrolase in low‐density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia

Increased activity of platelet‐activating factor acetylhydrolase in low‐density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia

Platelet-Activating Factor–Induced Ischemic Bowel Necrosis: The Effect of Platelet-Activating Factor Acetylhydrolase

Platelet‐activating factor: a mediator for clinicians

Contact Info

Product

Resources

About